Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.
Kadcyla is an Antibody Drug Conjugate (ADC), which combines the HER2-targeting properties of Herceptin (trastuzumab) and the cytotoxic chemotherapy agent DM1. In Kadcyla, trastuzumab and DM1 are joined together using a ‘stable linker’ to deliver DM1 directly to HER2-positive cancer cells.1
Kadcyla is approved as a single agent in the US, EU and many other countries for the treatment of people with HER2-positive advanced breast cancer who previously received Herceptin and taxane chemotherapy, separately or in combination.1
In Bangladesh Kadcyla is approved for the following indications.2
Kadcyla, as a single agent, is indicated for the treatment of patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane.
Kadcyla, as a single agent, is indicated for the adjuvant treatment adult of patients with HER2-positive early breast cancer who have residual disease, breast and/or lymph nodes after pre-operative systemic treatment that included HER2 targeted therapy.
For more disease and medicine related queries you may discuss with your physician.
In Bangladesh Kadcyla is available as
Vials 100 mg
Vials 160 mg
Are a woman who could become pregnant, or may be pregnant
If a patient becomes pregnant while receiving Kadcyla, or within 7 months following the last dose of Kadcyla, please immediately report pregnancy to the local RocheAdverse Event Line at
Additional information will be requested during a Kadcyla-exposed pregnancy and the first year of the infant’s life. This will enable Roche to better understand the safety of Kadcyla and to provide appropriate information to health authorities, healthcare providers, and patients
For additional information, please refer to
To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.
References:
Global Website: Products – Kadcyla. [Internet; cited 2018, November 08]. Retrieved from
Kadcyla-Product-Information-BD-Ro-05304020-December-2021
This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.